Literature DB >> 23622697

Characterization of mitotane (o,p'-DDD)--cyclodextrin inclusion complexes: phase-solubility method and NMR.

R Alfonsi1, D Attivi, A Astier, M Socha, S Morice, S Gibaud.   

Abstract

Mitotane (o,p'-dichlorodimethyl dichloroethane [o,p'-DDD]) is used for the treatment of adrenocortical cancer and occasionally Cushing's syndrome. This drug is very poorly soluble in water, and following oral administration, approximately 60% of the dose is recovered in the feces unaltered. The preparation of a soluble formulation (i.e. by complexation with cyclodextrins) with improved bioavailability is the aim of this work. The inclusion of mitotane in methyl-ß-cyclodextrins was studied using both phase-solubility methods and NMR experiments. To elucidate the inclusion mechanism, o,p'-DDD was compared to its regioisomer (i.e. p,p'-DDD). It was demonstrated that two dimethyl-ß-cyclodextrins (DMßCD) can complex with the aromatic rings. From the phase-solubility diagrams, we observe that both cases are very different: K(1:1) is between 37 000 and 85 000 mol.l(-1), whereas K(1:2) is between 5.3 and 32 mol.l(-1). The NMR experiments confirmed the inclusion but it also gave an insight into the kinetics of the dissociation: the ortho-chloro moiety is in slow exchange on the NMR time scale, whereas the para-chloro moiety is in fast exchange rate.
Copyright © 2013 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23622697     DOI: 10.1016/j.pharma.2013.02.001

Source DB:  PubMed          Journal:  Ann Pharm Fr        ISSN: 0003-4509


  2 in total

1.  The interaction between cucurbit[8]uril and baicalein and the effect on baicalein properties.

Authors:  Xiaodong Zhang; Jun Xie; Zhiling Xu; Zhu Tao; Qianjun Zhang
Journal:  Beilstein J Org Chem       Date:  2020-01-10       Impact factor: 2.883

Review 2.  The Challenging Pharmacokinetics of Mitotane: An Old Drug in Need of New Packaging.

Authors:  Malik Salman Haider; Taufiq Ahmad; Jürgen Groll; Oliver Scherf-Clavel; Matthias Kroiss; Robert Luxenhofer
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-07-21       Impact factor: 2.441

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.